Subarachnoid haemorrhage: older patients have low cerebral blood flow

CARL H A MEYER, DEREK LOWE, MARCIA MEYER, PETER L RICHARDSON, GLENN NEIL-DWYER

Abstract
Daily estimations of hemispheric cerebral blood flow using the xenon-133 inhalation technique were made in 116 patients during the first three weeks after subarachnoid haemorrhage. The patients' cerebral perfusion on average remained less than the normal perfusion expected for their age (based on a single estimation of cerebral blood flow in 67 volunteers). On each separate day after subarachnoid haemorrhage cerebral blood flow was inversely related to the patient's age. Older patients seem especially at risk of developing cerebral ischaemia after subarachnoid haemorrhage. The clinical outcome was more often unfavourable in older patients— that is, in those who tended to have the lowest cerebral blood flow.

Present results support the view that episodes of low cerebral blood flow lead to a poor outcome after subarachnoid haemorrhage. Because of the risk of inducing cerebral ischaemia great care should be exercised by physicians administering hypotensive drugs to older patients after subarachnoid haemorrhage.

Introduction
Patients who survive a subarachnoid haemorrhage may suffer further disability or death from recurrent haemorrhages or cerebral ischaemia.1–4 Cerebral ischaemia may occur, especially during the first two to three weeks after subarachnoid haemorrhage, whether or not surgery is performed to secure an aneurysm against recurrent haemorrhage. The eventual outcome of subarachnoid haemorrhage is more likely to be poor in older patients: this applies both to the natural history of the condition5 and to the results of surgery for ruptured aneurysms.6 This poses the question of whether the association between clinical outcome and patient age may be determined, in part at least, by changes occurring in cerebral blood flow after subarachnoid haemorrhage. Is there a particular risk that older patients may develop cerebral ischaemia? If so, does this affect their management by referring physicians and by neurosurgeons? We present a study of cerebral blood flow during the first three weeks after subarachnoid haemorrhage.

Subjects and methods
PATIENTS
During 1978-80, 116 patients (36 men, 80 women) aged 22-66 years (mean 47±11 years) were admitted to medical units and transferred to this regional neurosurgical unit as soon as possible after subarachnoid haemorrhage had been diagnosed. No patient suffered from established pulmonary or cardiovascular disease. The patients were nursed in bed, fed an unrestricted ward diet, and given a fluid input of 2-3 l daily.

The day, ending at midnight, on which subarachnoid haemorrhage occurred was referred to as day 1. Subsequent days, beginning at midnight, were then numbered consecutively. Daily estimations of hemispheric cerebral blood flow were made as often as possible between days 2 and 21. Individual patients, however, could not be studied on every single day during this period. Some patients, for example, were not referred until the second week after subarachnoid haemorrhage, some patients died before day 21, and some readings were missed for technical reasons.

Patients were given codeine (for pain) and phenytoin (as a prophylactic anticonvulsant). Further drug treatment was determined by the policy of whichever of three neurosurgeons was on duty when patients entered the unit. All 28 patients admitted under one surgeon were given tranexamic acid (6 g/day), which was stopped if angiography failed to show an aneurysm, if an aneurysm responsible for subarachnoid haemorrhage was successfully clipped at operation, or six weeks after the haemorrhage, whichever was applicable. Of the patients admitted under the two other surgeons, those who were admitted to the unit on days 1-3 were entered in a randomised double-blind trial (not reported here) concerned with the effects of
adrenergic-blocking drugs on the clinical course of subarachnoid haemorrhage. In all, 16 patients were given propranolol (80 mg eight-hourly) and phentolamine (20 mg three-hourly) while 17 patients were given only the propranolol. Adrenergic blockade was continued until after day 21. Apart from codeine and phenytoin no drug was given to the 55 other patients (including some of those admitted during days 1-3 and all of those admitted after day 3).

The source of subarachnoid haemorrhage was determined by cerebral angiography and was: cerebral aneurysm (92 patients) situated on the internal carotid artery (30), the middle cerebral artery (23), the anterior communicating artery complex (27), the pericallosal artery (four), and the verteobasilar system (eight); and cerebrovascular malformation (five). No source was found in 19 patients. In all, 124 angiograms were performed between days 2 and 20 (median, day 7). Craniotomy for treatment of a ruptured aneurysm was performed in 45 patients. Overall, there were 48 operations on days 3-20 (median, day 12). On days when surgery or angiography was done cerebral blood flow was studied before the procedure was carried out.

The eventual clinical outcome was assessed three months after the initial subarachnoid haemorrhage (see table I).

### TABLE I—Clinical outcome of subarachnoid haemorrhage (assessed by interview and by clinical examination three months after initial haemorrhage)

<table>
<thead>
<tr>
<th>Age group (years)</th>
<th>No of patients</th>
<th>Drug treatment</th>
<th>Clinical outcome*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Transaxanic acid</td>
<td>Adrenergic blockade</td>
</tr>
<tr>
<td></td>
<td></td>
<td>None</td>
<td>Excellent</td>
</tr>
<tr>
<td>20-49</td>
<td>58</td>
<td>16</td>
<td>18</td>
</tr>
<tr>
<td>50-66</td>
<td>47</td>
<td>10</td>
<td>12</td>
</tr>
<tr>
<td>20-49</td>
<td>42</td>
<td>9</td>
<td>15</td>
</tr>
<tr>
<td>50-66</td>
<td>40</td>
<td>9</td>
<td>15</td>
</tr>
</tbody>
</table>

*Outcome classified as: excellent—apparently full recovery; acceptable—mild residual deficit, but patients physically independent and capable of employment (or able to run a home) without requiring supervision or custodial care; or poor—patients capable of self-care but requiring supervision of activities, or not capable of self-care and/or severely disabled by dementia or dysphasia, or dead within three months (this last group comprised six patients in each age group).

<table>
<thead>
<tr>
<th>Age group (years)</th>
<th>Median No of daily estimations of mean cerebral blood flow (and interquartile range)</th>
<th>Lowest mean cerebral blood flow (ml/100 g/min)</th>
<th>Clinical outcome (N=105)</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-49</td>
<td>11 (6-16)</td>
<td>2.45 (1.35-4.50)</td>
<td>Excellent</td>
</tr>
<tr>
<td>30-45</td>
<td>15 (6-15)</td>
<td>3.75 (2.75-4.50)</td>
<td>5 (22)</td>
</tr>
<tr>
<td>40-50</td>
<td>12 (7-5)</td>
<td>2.35 (1.25-3.00)</td>
<td>5 (22)</td>
</tr>
<tr>
<td>50-66</td>
<td>10 (7-16)</td>
<td>2.35 (1.25-3.50)</td>
<td>5 (22)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age group (years)</th>
<th>No of patients</th>
<th>Median No of daily estimations of mean cerebral blood flow (and interquartile range)</th>
<th>Lowest mean cerebral blood flow (ml/100 g/min)</th>
<th>Clinical outcome (N=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-49</td>
<td>12 (6-16)</td>
<td>2.45 (1.35-4.50)</td>
<td>4 (17)</td>
<td>Excellent</td>
</tr>
<tr>
<td>30-45</td>
<td>15 (6-15)</td>
<td>3.75 (2.75-4.50)</td>
<td>5 (22)</td>
<td>5 (13)</td>
</tr>
<tr>
<td>40-50</td>
<td>12 (7-5)</td>
<td>2.35 (1.25-3.00)</td>
<td>5 (22)</td>
<td>5 (13)</td>
</tr>
<tr>
<td>50-66</td>
<td>10 (7-16)</td>
<td>2.35 (1.25-3.50)</td>
<td>4 (17)</td>
<td>4 (17)</td>
</tr>
</tbody>
</table>

### CONTROLS

A single estimation of cerebral blood flow was made for each of 67 volunteers (33 men, 34 women) aged 20-73 years (mean 42 ± SD 14 years), all of whom were fully alert and not taking any medication. None had ever suffered from any known neurological, cardiovascular, or pulmonary disease.

### ESTIMATION OF CEREBRAL BLOOD FLOW

Hemispherical cerebral blood flow was estimated using a method that combined the inhalation of xenon-133 with analysis of the initial slope of the clearance of 133Xe from the body. Subjects lay supine and simultaneously from the temporal region on each side of the head; the average of these two values was taken (mean cerebral blood flow). No attempt was made to adjust the readings to allow for PaCO₂. At the time of measurement of cerebral blood flow blood pressure was determined from the brachial artery using a pressure cuff sphygmomanometer. Mean arterial blood pressure was calculated as the sum of the diastolic blood pressure and one-third of the pulse pressure.

### STATISTICAL METHODS

Standard statistical procedures were used—namely, the x² test and the correlation and regression technique. Significance implies a probability more extreme than p=0.05 (two-tailed test).
Results

MEAN CEREBRAL BLOOD FLOW IN CONTROLS

The resting mean cerebral blood flow in the controls, estimated in each case with \( P_{\text{CO}_2} \) between 4.0 and 6.5 kPa (30 and 49 mm Hg), was inversely related to age (fig 1).

![Graph showing mean cerebral blood flow vs age in controls](image)

FIG 1—Relation between mean cerebral blood flow and age in controls \((n = 67, r = -0.73, p < 0.001)\).
Regression line: Mean cerebral blood flow = 59.1 − 0.34 age.

MEAN CEREBRAL BLOOD FLOW IN PATIENTS

Relation with age

When all patients with subarachnoid haemorrhage were considered, regardless of drug treatment, resting mean cerebral blood flow was inversely related to patient age for each of the days between days 2 and 21. The number of patients tested on each day ranged from 46 to 74 (median 66), and the linear correlation coefficients ranged from −0.48 to −0.71 (median −0.56) (in each case \( p < 0.001 \)). The coefficients were virtually unchanged by adjustment for end-tidal \( P_{\text{CO}_2} \) or for mean arterial blood pressure.

The fall in mean cerebral blood flow with advancing age was not exaggerated by including patients taking tranexamic acid or adrenergic-blocking drugs. When the relation between mean cerebral blood flow and age was considered for each drug group separately the linear correlation coefficients on individual days varied as follows: patients receiving no drugs, range −0.49 to −0.80 (median −0.59); patients receiving adrenergic blockade, −0.49 to −0.81 (median −0.62); and patients receiving tranexamic acid, −0.04 to −0.83 (median −0.43). The number of patients tested daily varied as follows: patients receiving no drugs, range 16-35 (median 29); patients receiving adrenergic blockade, 20-27 (median 23); and patients receiving tranexamic acid, 8-16 (median 11).

Relation with time after haemorrhage

On most days the patients studied included some who had undergone angiography and a few who had undergone surgery for aneurysm during the previous few days. No patient studied on day 2, however, had undergone either procedure, and only two of those studied on day 3 had undergone angiography. On each of these days the association between mean cerebral blood flow and age was strong (all patients regardless of drug group: on day 2 \( n = 46, r = -0.71 \); on day 3 \( n = 50, r = -0.65 \)). Figure 2 shows values of mean cerebral blood flow on day 5; the scatter was typical of that occurring on other days. On the whole, regression lines for days 2-21 (fig 3) were roughly parallel.

There was a progressive downward trend in mean cerebral blood flow during the first week after subarachnoid haemorrhage, a trend observable for each of the three drug groups considered separately.

The linear relation between mean cerebral blood flow and age was similar in both the patients and controls (similar slopes of regression lines in fig 3), but after subarachnoid haemorrhage cerebral blood flow was reduced (different positions of regression lines) by an amount that for any single day was constant regardless of patient age.

CLINICAL OUTCOME OF SUBARACHNOID HAEMORRHAGE

In considering clinical outcome we excluded 11 patients—namely four whose deaths followed directly from surgical mishap (aneurysmal rupture during operation), four whose deaths were due to spontaneous recurrent haemorrhage (confirmed by lumbar puncture or computed axial tomography of the brain or both), and three whose eventual outcome could not be traced.

Relation with age

The outcome was less good in patients aged 50-66 years than in patients aged 20-49 years (table I). This was so whether we considered patients with subarachnoid haemorrhage from any source or only those whose haemorrhage came from aneurysms shown by angiography. The two age groups did not differ significantly in the relative numbers of patients taking tranexamic acid, adrenergic blockade, or no drugs.

Relation with mean cerebral blood flow

Since the number of daily estimations of cerebral blood flow (median 12) made during the three weeks after subarachnoid haemorrhage differed among the patients some caution is needed in interpreting table II, which gives the lowest daily value of cerebral blood
flow in each patient. When all patients were considered regardless of drug treatment very low cerebral blood flow was linked with poor clinical outcome whether patients were young or old and was more common in the older patients. When the lowest mean cerebral blood flow was $>$ 30 ml/100 g/min the outcome tended to be better, but the older patients were less likely to have an excellent outcome than those who were younger. These observations remained the same when patients who received no drugs were studied on their own.

Discussion
Our findings in normal subjects studied under resting conditions confirm that cerebral blood flow falls with advancing age. In particular, the values of normocapnic cerebral blood flow and its decline with age were similar to results obtained by others using the same method for calculating cerebral blood flow.

Our results indicate that cerebral blood flow falls progressively below normal during the first week after subarachnoid haemorrhage and remains abnormally low for at least another two weeks. For each separate day during this period the oldest patients tended to have the lowest cerebral blood flow. We found this to be so whether patients were treated with adrenergic blockade, tranexamic acid, or neither of these. Treatment with adrenergic-blocking drugs or tranexamic acid did not selectively depress the cerebral blood flow of the older patients.

This study supports the view that subarachnoid haemorrhage is more likely to have a poor outcome in older patients. Even when cerebral blood flow was relatively preserved (lowest mean value $>$ 30 ml/100 g/min) the overall outcome was worse in patients aged over 50, which suggests that age-related factors other than resting cerebral blood flow may influence the clinical result. The relevance of cerebral blood flow, however, seems beyond question. Whether patients were young or old, very low mean cerebral blood flow ($<$ 30 ml/100 g/min) was associated with a poor clinical outcome. Such very low values occurred more commonly in the older patients. This suggests that the occurrence of very low flow is important in determining the association between clinical outcome and age.

The level of cerebral blood flow that is critical for neurological function depends on factors such as the speed with which the flow falls, the period for which it remains low, the part of the brain affected, and the state of cerebral metabolism. As cerebral perfusion falls below 20 ml/100 g/min, however, rapid changes in neurological function occur that may progress to neuronal death. By lowering cerebral blood flow subarachnoid haemorrhage reduces the margin that normally exists between a subject's cerebral blood flow and the ischaemic threshold. In general, older patients tend to come closer to the ischaemic threshold for cerebral ischaemia. Subarachnoid haemorrhage is also associated with impairment of the cerebrovascular reactivity (autoregulation) that normally prevents cerebral blood flow from falling when cerebral perfusion pressure is reduced. When autoregulation is lost after subarachnoid haemorrhage cerebral blood flow may fall further if systemic blood pressure is reduced, whether spontaneously or as a result of therapeutic measures, or if there is narrowing ("vasospasm") of intracranial arteries. In such circumstances patients who are old would be more vulnerable since their cerebral blood flow would have less far to fall before reaching the ischaemic threshold.

What are the clinical implications? Physicians faced with patients after a recent subarachnoid haemorrhage are concerned with their initial management and subsequent referral to a neurosurgical unit. Some workers advise that the likelihood of further bleeding from an unclipped aneurysm may be reduced by deliberately lowering the arterial blood pressure. This measure, however, may lead to cerebral ischaemia, especially in older patients, who, with their cerebral blood flow already low after the haemorrhage, are particularly vulnerable to the added effects of hypovolaemia and hypotension.

Whatever the patient's age, the risk of recurrent haemorrhage from a ruptured aneurysm is best countered by operative treatment of the aneurysm, provided that the patient is fit for surgery. In managing older patients (before, during, and after surgery) it should be remembered that the low (and falling) cerebral blood flow may well be a major factor in determining the outcome. Accordingly, particular care should be taken to avoid prolonged hypotension during surgery, to ensure good hydration at all times, and to ensure adequate pulmonary function (brains at risk from ischaemia should not be further threatened by hypoxia).

Ideally, surgery for a ruptured aneurysm should be performed soon after the initial subarachnoid haemorrhage to pre-empt recurrent haemorrhage and at a time when the risk of operative complications such as ischaemia is acceptably low. In individual patients the progressive fall in cerebral blood flow during the first week or two after subarachnoid haemorrhage may ultimately render the blood flow sufficiently low to compromise operations for ruptured aneurysms or to impair the clinical state so that surgery is deferred (with the risk that further haemorrhage will occur during the delay). This emphasises that clinically fit patients should be referred to neurosurgeons soon after their initial haemorrhage, within the first day if possible. This practice is widely accepted for patients who are young but also applies to patients who are old and whose low levels of cerebral blood flow may make the timing of angiography and surgery particularly critical. Clearly these older patients require careful management.

We thank Mr J R Bartlett and Mr R S Maurice-Williams for allowing us to study patients admitted under their care; Dr N Veall, Mr J Crawley, and Dr J James for advice concerning the estimation of cerebral blood flow; and Miss P Frost and Mr M Cowan for technical aid.

References
3. Crompton MR. Cerebral infarction following the rupture of cerebral berry aneurysms. Brain 1964;87:263-79.
Disseminated malignant phaeochromocytoma: localisation with iodine-131-labelled meta-iodobenzylguanidine

HELEN SUTTON, PAUL WYETH, A P ALLEN, O A THURTLE, T K HAMES, M I D CAWLEY, DUNCAN ACKERY

Abstract
Meta-iodobenzylguanidine, a guanethidine analogue, is a newly synthesised substance capable of imaging the adrenal medulla. In a woman in whom phaeochromocytoma had been diagnosed iodine-131-labelled meta-iodobenzylguanidine was given intravenously; gamma-camera images showed bilateral adrenal tumours and uptake corresponding to bone and liver metastases. 131I-meta-iodobenzylguanidine is effective in localising phaeochromocytomas, and the technique is safe, specific, and non-invasive.

Introduction
No agent had been found that was capable of imaging the adrenal medulla until the University of Michigan Medical School synthesised iodine-131-labelled meta-iodobenzylguanidine, a guanethidine analogue, which is structurally similar to noradrenaline and taken up by adrenergic storage vesicles.1 This correctly localised eight proved phaeochromocytomas.2 We describe, for the first time in this country, localisation of disseminated malignant phaeochromocytoma using this substance, made at Southampton.

Case report
A 52-year-old woman was admitted for investigation of an eight-month history of widespread bone pain, arthralgia, excessive sweating, Raynaud’s phenomenon, palpitations, central chest pain, and weight loss (8 kg). She was sweating profusely and was wasted, with peripheral skin mottling. She had a regular tachycardia (150 beats/min). Blood pressure was 150/130 mm Hg. There were bilateral frenal haemorrhages and exudates. Over the next five weeks she had frequent episodes of palpitations and central chest pain associated with Raynaud’s phenomenon in the hands and livedo reticularis in the legs. Blood pressure rose to 240/160 mm Hg, returning to 150/130 mm Hg.

On admission haemoglobin concentration was 9.7 g/dl (normochromic). Biochemical profile was normal except for a raised alkaline phosphatase activity. Serum calcium concentration was 2.56 mmol/l (10.5 mg/100 ml), and calciitonin concentration 0.1 μg/l (normal <0.08 μg/l). Twenty-four-hour urine total metanephrines were 340 μmol/24 hours (63 mg/24 hours; normal <7 μmol/24 hours (<1.3 mg/24 hours)) (metanephrine 39.5 μmol/24 hours (8 mg/24 hours), normetanephrine 300 μmol/24 hours (55 mg/24 hours)). Radiographs and results of ultrasonography were equivocal, but bone images (technetium-99m-labelled (methylene(diphosphonate) showed widespread metastases. Liver images (Te-99m-sulphur colloid) showed no focal deposits but suggested a mass above the right kidney. Selective venous sampling was of no help in localising the tumour. Plasma noradrenaline concentration ranged from 5.6 to 12.0 μg/l (normal <1 μg/l). Disseminated malignant phaeochromocytoma was diagnosed. Histological confirmation from bone biopsy was not sought because of the risk of pathological fracture. Chemotherapy or radiotherapy was considered not to be indicated. Treatment with phenoxybenzamine 100 mg and propranolol 40 mg, both four times daily, and various analgesics resulted in moderately good control of the pain and cardiovascular symptoms, and she was discharged. Two months later she was readmitted with increased bone pain and postural hypotension.

Meta-iodobenzylguanidine was prepared as described by Wieland et al.3 Animal toxicity studies in 32 Sprague Dawley rats showed no ill effect from 1200 times the imaging dose intended for man. Meta-iodobenzylguanidine was labelled with 131I and administered intravenously. Gamma-camera images showed bilateral adrenal tumours, widespread bone uptake corresponding to the metastases shown on the bone images, and uptake in the liver corresponding to focal metastases present on repeat liver images (figure).

Discussion
Phaeochromocytoma is rare, occurring in about one in 10 000 of the general population. The diagnosis is often made only at necropsy. Of 54 tumours proved at necropsy, 13 had been correctly diagnosed during life.4 Plasma or urinary catecholamine concentrations may be diagnostic, but successful management depends on localising the tumour. Imaging

References

(Accepted 5 August 1982)